Clinical trials: Cancer of Oropharynx
Head and Neck Cancer
Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00352105
- Testing
- cisplatin, fluorouracil, Iressa
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- David Adelstein
Head and Neck Cancer, Precancerous/Nonmalignant Condition
Photodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract
RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, precancerous cells and cancer cells are killed.
- Trial name
- NCT00453336
- Testing
- Porfimer Sodium, Photodynamic Therapy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Miami
Oropharyngeal Cancer, HPV-Related Squamous Cell Carcinoma
PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing
Enrollment is only available to patients enrolled on the Optima II study (NCT03107182). The purpose of this trial is to compare rates of opioid use at completion of radiation for patients with Common Terminology Criteria for…
- Trial name
- NCT03423264
- Testing
- Gabapentin
- Where
- United States
- Sponsor
- University of Chicago
Speech Intelligibility
Task of Acoustic-phonetic Decoding on Anatomic Deficits in Paramedical Assessment of Speech Disorders for Patients Treated for Oral or Oropharyngeal Cancer
The bridging of the gap between speech production and perception by the interlocutor would be made possible by the use of a more suitable and automatic task. An acoustic-phonetic decoding test (or DAP in French, i.e.
- Trial name
- DAPADAF-E (NCT04742998)
- Testing
- Acoustic-phonetic decoding task (DAP)
- Where
- 3 sites in France
- Volunteers
- 116 people
- Sponsor
- University Hospital, Toulouse
Head and Neck Cancer
Perifosine in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase II trial to study the effectiveness of perifosine in treating patients who have recurrent or metastatic head and neck cancer.
- Trial name
- NCT00062387
- Testing
- perifosine
- Where
- 12 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
The study is an open-label phase I/II clinical trial. The study will enroll patients to receive neoadjuvant SBRT plus 1 or 2 doses of neoadjuvant pembrolizumab with concurrent ficerafusp alfa (4 doses) prior to definitive…
- Trial name
- NCT07552558
- Testing
- Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Washington University School of Medicine
Head and Neck Cancer
AP5346 or Oxaliplatin in Treating Patients With Metastatic and/or Unresectable Recurrent Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as AP5346 and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00415298
- Testing
- DACH polymer platinate AP5346, oxaliplatin, gene expression analysis
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, San Diego
Head and Neck Cancer, Long-term Effects Secondary to Cancer Therapy in Adults
Side Effects of High-Dose Intensity-Modulated Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
RATIONALE: Tests that measure how much saliva is made, hearing, swallowing, voice function, and quality of life may improve the ability to plan treatment for patients with advanced head and neck cancer and may help doctors find…
- Conditions
- Head and Neck Cancer, Long-term Effects Secondary to Cancer Therapy in Adults, Oral Complications of Radiation Therapy, Radiation Toxicity
- Trial name
- NCT00415025
- Testing
- adjuvant therapy, management of therapy complications, quality-of-life assessment
- Volunteers
- 20 people
- Sponsor
- University of Wisconsin, Madison
Head and Neck Cancer
Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Stage III or Stage IV Head and Neck Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00005814
- Testing
- cetuximab, cisplatin, radiation therapy
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal HPV-Positive Squamous Cell Carcinoma
Biomarker-Driven Radiation Therapy Dose Reduction After Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer
This phase II trial tests whether reduced dose radiation therapy after transoral robotic surgery works in treating patients with human papillomavirus (HPV)-positive oropharyngeal cancer.
- Trial name
- NCT05387915
- Testing
- Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Emory University
Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Dual-energy CT vs. MRI in the Evaluation of Squamous Cell Carcinomas of the Oral Cavity and Oropharynx
The diagnostic and pre-therapeutic assessment of squamous cell carcinomas requires a neck and chest CT scan and a neck and facial MRI, which is the most effective examination, to establish the TNM stage of the tumor.
- Trial name
- DECT-CEco (NCT07343271)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
Solid Tumors With PTCH1 Loss-of-function Mutations
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
This study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF)…
- Trial name
- NCT05199584
- Testing
- ENV-101 (taladegib)
- Where
- 16 sites in United States
- Volunteers
- 20 people
- Sponsor
- Endeavor Biomedicines, Inc.
Head and Neck Cancer
Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer
Current therapies for advanced Head and Neck Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of advanced Head and Neck…
- Trial name
- NCT00003489
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Burzynski Research Institute
Oropharyngeal Squamous Cell Carcinoma, HPV-mediated Oropharyngeal Squamous Cell Carcinoma
Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.
The goal of this study is to evaluate if a shorter course of therapy can improve the quality of life in patients receiving radiation therapy after trans-oral robotic surgery.
- Trial name
- RAD RAPTORS (NCT07044635)
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Utah
PREDICTIVE BIOMARKERS, Evaluation of HPV-specific E5 Transcript Expression in a Cohort of Patients With HPV-associated OPC
New Prognostic and Predictive Biomarkers for HPV-associated Oropharyngeal Cancer
The study involves the coexistence of a retrospective part, in which a group of patients with HPV-associated OPC for whom follow-up data of at least 2 years after diagnosis are available, designed in order to evaluate the…
- Conditions
- PREDICTIVE BIOMARKERS, Evaluation of HPV-specific E5 Transcript Expression in a Cohort of Patients With HPV-associated OPC, HPV 16 Positive Oropharyngeal Tumors (OPC)
- Trial name
- NCT06097936
- Testing
- HPV-ASSOCIATED OROPHARYNGEAL CANCER
- Where
- Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Regina Elena Cancer Institute
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
This phase Ib trial tests the safety, side effects and best dose of tumor membrane vesicle (TMV) vaccine therapy alone and in combination with pembrolizumab and evaluates how well it works in treating patients with head and neck…
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT06868433
- Testing
- Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Emory University
Oropharynx Cancer, Radiotherapy; Complications
Adaptive RadioTherapy for OroPharynx Cancer
This is a phase II randomized trial, where patients with histologically proven squamous cell carcinoma of oropharynx that have primary tumor (T3 - T4) in place, treated with curative intent chemoradiation, will be randomized to…
- Conditions
- Oropharynx Cancer, Radiotherapy; Complications, Radiotherapy Side Effect, Dysphagia
- Trial name
- ART-OPC (NCT04901234)
- Testing
- Standard radiotherapy +/- chemotherapy, Experimental radiotherapy +/- chemotherapy
- Where
- 2 sites in Australia, Canada
- Volunteers
- 120 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Head and Neck Cancer
Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00720304
- Testing
- docetaxel, erlotinib hydrochloride, fluorescence in situ hybridization
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Case Comprehensive Cancer Center
Pulmonary Disease, Oropharyngeal Disease
Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
This study will examine bacteria and toxins in the mouth, lung and digestive system that may be the cause of various diseases or symptoms. H.
- Conditions
- Pulmonary Disease, Oropharyngeal Disease, Lymphangioleiomyomatosis, Pulmonary Fibrosis
- Trial name
- NCT00366509
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Head and Neck Cancer
Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00566540
- Testing
- Cisplatin, Paclitaxel, Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Ohio State University Comprehensive Cancer Center